OBJECTIVE: Chronic immune activation and elevated numbers of circulating activated monocytes (CD16) are implicated in HIV-associated neuroinflammation. The objective was to compare the level of circulating CD16 monocytes and IFN-γ-inducible protein 10 (IP-10) between HIV-infected cannabis users (HIV+MJ+) and noncannabis users (HIV+MJ-) and determine whether in-vitro Δ-Tetrahydrocannabinol (THC), a constituent of cannabis, affected CD16 expression as well as IP-10 production by monocytes. DESIGN: The levels of circulating CD16 monocytes and IP-10 from HIV+MJ- and HIV+MJ+ donors were examined. In-vitro experimentation using THC was performed on primary leukocytes isolated from HIV-MJ-, HIV+MJ- and HIV+MJ+ donors to determine if THC has an impact on CD16 monocyte and IP-10 levels. METHODS: Flow cytometry was used to measure the number of blood CD16 monocytes and plasma IP-10 from HIV+MJ- and HIV+MJ+ donors. Peripheral blood mononuclear cells were isolated from HIV-MJ- and HIV+ (MJ- and MJ+) donors for in-vitro THC and IFNα treatment, and CD16 monocytes and supernatant IP-10 were quantified. RESULTS: HIV+MJ+ donors possessed a lower level of circulating CD16 monocytes and plasma IP-10, compared with HIV+MJ- donors. Further, monocytes from HIV+MJ+ donors were unable to induce CD16 expression when treated with in-vitro IFNα, whereas HIV-MJ- and HIV+MJ- donors displayed pronounced CD16 induction, suggesting anti-inflammatory effects by cannabis. Lastly, in-vitro THC treatment impaired CD16 monocyte transition to CD16 and monocyte-derived IP-10. CONCLUSION: Components of cannabis, including THC, may decelerate peripheral monocyte processes that are implicated in HIV-associated neuroinflammation.
OBJECTIVE: Chronic immune activation and elevated numbers of circulating activated monocytes (CD16) are implicated in HIV-associated neuroinflammation. The objective was to compare the level of circulating CD16 monocytes and IFN-γ-inducible protein 10 (IP-10) between HIV-infected cannabis users (HIV+MJ+) and noncannabis users (HIV+MJ-) and determine whether in-vitro Δ-Tetrahydrocannabinol (THC), a constituent of cannabis, affected CD16 expression as well as IP-10 production by monocytes. DESIGN: The levels of circulating CD16 monocytes and IP-10 from HIV+MJ- and HIV+MJ+ donors were examined. In-vitro experimentation using THC was performed on primary leukocytes isolated from HIV-MJ-, HIV+MJ- and HIV+MJ+ donors to determine if THC has an impact on CD16 monocyte and IP-10 levels. METHODS: Flow cytometry was used to measure the number of blood CD16 monocytes and plasma IP-10 from HIV+MJ- and HIV+MJ+ donors. Peripheral blood mononuclear cells were isolated from HIV-MJ- and HIV+ (MJ- and MJ+) donors for in-vitro THC and IFNα treatment, and CD16 monocytes and supernatant IP-10 were quantified. RESULTS: HIV+MJ+ donors possessed a lower level of circulating CD16 monocytes and plasma IP-10, compared with HIV+MJ- donors. Further, monocytes from HIV+MJ+ donors were unable to induce CD16 expression when treated with in-vitro IFNα, whereas HIV-MJ- and HIV+MJ- donors displayed pronounced CD16 induction, suggesting anti-inflammatory effects by cannabis. Lastly, in-vitro THC treatment impaired CD16 monocyte transition to CD16 and monocyte-derived IP-10. CONCLUSION: Components of cannabis, including THC, may decelerate peripheral monocyte processes that are implicated in HIV-associated neuroinflammation.
Authors: Margaret Haney; Erik W Gunderson; Judith Rabkin; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin Journal: J Acquir Immune Defic Syndr Date: 2007-08-15 Impact factor: 3.731
Authors: Dionna W Williams; Tina M Calderon; Lillie Lopez; Loreto Carvallo-Torres; Peter J Gaskill; Eliseo A Eugenin; Susan Morgello; Joan W Berman Journal: PLoS One Date: 2013-07-26 Impact factor: 3.240
Authors: Rowan Saloner; Laura M Campbell; Vanessa Serrano; Jessica L Montoya; Elizabeth Pasipanodya; Emily W Paolillo; Donald Franklin; Ronald J Ellis; Scott L Letendre; Ann C Collier; David B Clifford; Benjamin B Gelman; Christina M Marra; J Allen McCutchan; Susan Morgello; Ned Sacktor; Dilip V Jeste; Igor Grant; Robert K Heaton; David J Moore Journal: J Int Neuropsychol Soc Date: 2019-03-20 Impact factor: 2.892
Authors: Patrick O'Connell; Yuliya Pepelyayeva; Maja K Blake; Sean Hyslop; Robert B Crawford; Michael D Rizzo; Cristiane Pereira-Hicks; Sarah Godbehere; Linda Dale; Peter Gulick; Norbert E Kaminski; Andrea Amalfitano; Yasser A Aldhamen Journal: J Immunol Date: 2018-12-10 Impact factor: 5.422
Authors: Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis Journal: Pharmacol Biochem Behav Date: 2019-01-26 Impact factor: 3.533
Authors: Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski Journal: J Neuroimmune Pharmacol Date: 2020-05-14 Impact factor: 4.147
Authors: Joseph E Henriquez; Michael D Rizzo; Robert B Crawford; Peter Gulick; Norbert E Kaminski Journal: J Pharmacol Exp Ther Date: 2018-07-19 Impact factor: 4.030
Authors: Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2020-09-15 Impact factor: 4.147
Authors: Michael D Rizzo; Robert B Crawford; Anthony Bach; Sera Sermet; Andrea Amalfitano; Norbert E Kaminski Journal: J Pharmacol Exp Ther Date: 2019-08-05 Impact factor: 4.030
Authors: Jessica S Flannery; Michael C Riedel; Taylor Salo; Ranjita Poudel; Angela R Laird; Raul Gonzalez; Matthew T Sutherland Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2021-07-03 Impact factor: 5.067